This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic markers, with a favorable safety profile.